
    
      For the study will be recruited 60 women treated with breast cancer, using tamoxifen or
      aromatase inhibitor, are in menopause, hot flashes and has with or without sexual life. They
      will answer the questionnaires: Kupperman, World Health Organization Quality of Life (WHOQOL)
      and those sexually active will have Female Sexual Function Index (FSFI). The control group
      will have 30 patients using tamoxifen alone or inhibitor. The other group will have 30
      patients receiving tamoxifen or inhibitor and will start with 2 tablets per day of dry
      extract of Cimicifuga racemosa. They will be followed for 6 months and answer questionnaires
      at the first visit, 3-month and 6-month follow-up.
    
  